Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II

Affiliations

• ¹ Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
• ² Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
• ³ Center for Melanoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, United States.
• ⁴ Laboratory Animal Center, Xiamen University, Xiamen, China.
• ⁵ School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
• ⁶ Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
• ⁷ Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China.
• ⁸ Suzhou Industrial Park Monash Research Institute of Science and Technology, Suzhou, China.
• ⁹ School of Population Medicine and Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.